Sernova and Seraxis Merge to Form BetaNova, Targeting Type 1 Diabetes Cell Therapy
SEOVF sits 25% above its 52-week low of $0.065 on light trading volume (0.4× avg).
Summary
Sernova Biotherapeutics and Seraxis Holdings announced a definitive merger agreement to create BetaNova Biotherapeutics, a clinical-stage company focused on type 1 diabetes islet cell replacement. The combined entity will be U.S.-domiciled with shareholders of each company owning approximately 50%. A $10 million non-brokered convertible note financing from insiders will fund operations through key milestones, including cGMP manufacturing of SR-02, dosing first patients in a Phase 1/2 trial in Q1 2027, and Nasdaq listing readiness. The merger combines Sernova's Cell Pouch Bio-hybrid Organ with Seraxis' stem cell-derived islet cells and manufacturing platform. Sernova's Phase 1/2 study with donor islets met all primary and secondary endpoints, providing clinical validation. The transaction requires shareholder approval (expected Q4 2026), TSX listing approval, and court approval. A webinar is scheduled for September 11 to discuss the merger. This follows Sernova's FDA Orphan Drug Designation for its AIT therapy in June 2026, reinforcing the company's focus on diabetes cell therapy.
At the time of this announcement, SEOVF was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $30.7M. The 52-week trading range was $0.07 to $0.16. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.